NCT01031927COMPLETEDanonymous

Sarcosine as Primary or Adjunctive Therapy in Obsessive Compulsive Disorder: A Prospective, Open-label Study

Sponsor

Source record

China Medical University Hospital

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

Obsessive Compulsive Disorder (OCD)

Indication / condition

AI-normalized

Obsessive Compulsive Disorder

Intervention

Source record

N-methyl glycine

Related intelligence directories

Indication directory: Obsessive Compulsive Disorder Modality directory: small molecule Target directory: Obsessive Compulsive Disorder (OCD)

Source & freshness

Source record

NCT ID

NCT01031927

Original source

ClinicalTrials.gov

Source last updated

Dec 29, 2009

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT01031927

Title

Sarcosine as Primary or Adjunctive Therapy in Obsessive Compulsive Disorder: A Prospective, Open-label Study

Sponsor

China Medical University Hospital

Status

COMPLETED

Phase

Phase 2

Condition raw

Obsessive Compulsive Disorder

Condition normalized

Obsessive Compulsive Disorder

Modality raw

Obsessive Compulsive Disorder

Modality normalized

small molecule

Target raw

Obsessive Compulsive Disorder (OCD)

Target normalized

Obsessive Compulsive Disorder (OCD)

Interventions

N-methyl glycine

Public preview

Source record

This clinical trial evaluated the efficacy and safety of N-methyl glycine (sarcosine) as a treatment for OCD. Conducted by China Medical University Hospital, the study involved 30 participants over a 10-week period, focusing on the drug's potential to modulate glutamatergic dysfunction associated with OCD.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Sarcosine as Primary or Adjunctive Therapy in Obsessive Compulsive Disorder: A Prospective, Open-label Study

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT01031927

Status

COMPLETED

Phase

Phase 2

Sponsor

China Medical University Hospital

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedDec 29, 2009

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01031927

Indication

Obsessive Compulsive Disorder

Modality

small molecule

Target

Obsessive Compulsive Disorder (OCD)

Intervention

N-methyl glycine

Source record